NCT05274425 - A 24-week rPMS Study in Real-world Setting for Enerzair | Biotech Hunter

Enrollment

600

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

March 11, 2027

Study Completion Date

March 11, 2027

Conditions

Asthma

Interventions

OTHER

Enerzair 150/50/80 μg

There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.

OTHER

Enerzair 150/50/160 μg

There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (16)

10475

RECRUITING

Novartis Investigative Site, Deogyang Gu Goyang Si

13620

RECRUITING

Novartis Investigative Site, Bundang Gu

14584

WITHDRAWN

Novartis Investigative Site, Bucheon-si

26426

RECRUITING

Novartis Investigative Site, Wŏnju

28644

RECRUITING

Novartis Investigative Site, Cheongju-si

42602

RECRUITING

Novartis Investigative Site, Daegu

49201

RECRUITING

Novartis Investigative Site, Busan

501171

RECRUITING

Novartis Investigative Site, Gwangju

705703

RECRUITING

Novartis Investigative Site, Daegu

561 712

RECRUITING

Novartis Investigative Site, Jeonju

540-719

RECRUITING

Novartis Investigative Site, Suncheon

630-522

RECRUITING

Novartis Investigative Site, Gyeongsangnam Do

03722

RECRUITING

Novartis Investigative Site, Seoul

04763

RECRUITING

Novartis Investigative Site, Seoul

05505

RECRUITING

Novartis Investigative Site, Seoul

06273

RECRUITING

Novartis Investigative Site, Seoul